Core Viewpoint - Guosheng Zhike's financial performance in 2024 shows a decline in both revenue and net profit, indicating significant market pressure despite advancements in technology and product development [4][7]. Financial Performance - In 2024, Guosheng Zhike reported an operating revenue of 1.037 billion yuan, a year-on-year decrease of 6.04%, and a net profit attributable to shareholders of 128 million yuan, down 10.30% year-on-year [4][5]. - The company's gross profit also declined, reaching 250 million yuan, a decrease of 5.66% year-on-year, highlighting challenges in cost control and product pricing [4][6]. - The non-recurring net profit fell by 11.45% year-on-year, indicating limited contributions from non-operating income to overall profitability [4][5]. Technological Innovation - Despite the financial downturn, Guosheng Zhike made significant strides in technology innovation, with R&D expenditures reaching 53.9032 million yuan, accounting for 5.20% of operating revenue, an increase of 0.19 percentage points year-on-year [5][6]. - The company obtained 47 new intellectual property rights, bringing the total to 327, reflecting ongoing investment in technology development [5][6]. Market Development - Guosheng Zhike intensified its market expansion efforts in 2024, particularly in the mold, semiconductor, and civil aviation sectors, successfully acquiring several industry benchmark clients [7]. - The company accelerated its overseas market layout, participating in international exhibitions and increasing the number of overseas clients [7]. Resource Integration - The company optimized production processes and improved on-time delivery capabilities, reinforcing its advantages in the supply chain [7]. - Orders for the precision sheet metal business of its subsidiary increased, demonstrating effective resource sharing within the group [7]. Future Challenges - Despite progress in technology innovation and market expansion, the decline in overall operating revenue suggests that the company needs to adjust its strategy in response to changing market demands and competitive pressures [7]. - To ensure sustainable development, the company must increase investment in core business areas and enhance market competitiveness [7].

翰宇药业（300199）向记者表示，"公司目前对美销售的产品主要是利拉鲁肽和一些原料药，我们与合 作伙伴正密切关注相关动态，相关应对需要美国征收药品关税的具体情况明晰之后再研究。公司也一直 计划开拓欧洲或东南亚市场，以降低对美国市场的依赖。"(智通财经) ...